Eli Lilly said its experimental weight-loss pill orforglipron produced a 12.4% average reduction in body weight at the highest dose after 72 weeks in the late-stage ATTAIN-1 trial, compared with a 0.9% decline for placebo. Roughly 60% of participants on the top dose shed at least 10% of their weight, but dropout rates reached 24% and gastrointestinal side-effects were common. The result, which falls short of the 13–15% loss many analysts expected and lags injectable rivals such as Wegovy and Lilly’s own Zepbound, prompted investors to reassess the pill’s commercial potential. The data overshadowed a strong quarterly report and sent Lilly shares tumbling almost 14% in early New York trading, the steepest single-day decline since August 2000. Shares of competitor Novo Nordisk, which is developing its own oral obesity therapy, rose about 8–10% on the news. For the second quarter Lilly posted revenue of $15.56 billion, up 38% from a year earlier, and adjusted earnings of $6.31 a share, both comfortably ahead of consensus. Sales of injectable GLP-1 drugs remained the main engine, with Mounjaro generating $5.20 billion and Zepbound $3.38 billion. Bolstered by those products, the company lifted its full-year outlook to $60–62 billion in revenue and $21.75–$23.00 in adjusted earnings per share. Lilly said it plans to submit orforglipron to regulators before the end of the year, positioning the pill as a convenient alternative to weekly injections despite its lower efficacy.